Celgene Corporation (CELG) stock prices updated...
 

Celgene Corporation stock price

Celgene Corporation latest news:


  • 08/10/2017 11:39:46

    BRIEF-Celgene Corp says on August 10, co issued $500 million aggregate principal amount of 2.250% senior notes due 2021

    * Celgene Corp - on August 10, 2017, co issued $500 million aggregate principal amount of 2.250% senior notes due 2021 - SEC filing Source text - (http://bit.ly/2hNCc4D) Further company coverage:

  • 08/01/2017 11:50:59

    BRIEF-Celgene says monthly wholesale acquisition cost of AML treatment Idhifa is $24,872

    * Says monthly wholesale acquisition cost of AML treatment Idhifa is $24,872 Further company coverage:

  • 08/01/2017 09:21:18

    FDA approves leukemia treatment developed by Celgene, Agios

    Aug 1 (Reuters) - The U.S. Food and Drug Administration (FDA) on Tuesday approved Celgene Corp and Agios Pharmaceuticals Inc's treatment for acute myeloid leukemia (AML) patients with a specific genetic mutation.

  • 07/25/2017 18:42:49

    Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs

    The lawsuit accused the pharmaceutical company of marketing Thalomid and Revlimid for unapproved use on a broader range of cancers.

  • 07/25/2017 14:57:25

    Celgene Corp. to pay $280 million to settle lawsuit alleging it promoted cancer drugs for unapproved uses

    Celgene Corp. to pay $280 million to settle lawsuit alleging it promoted cancer drugs for unapproved uses.

  • 07/06/2017 12:07:00

    Here's Why BeiGene Ltd. Rose as Much as 31.4% on Thursday

    The mid-cap Chinese biopharma announced a collaboration with Celgene that has a few interesting twists to it.

  • 06/14/2017 09:11:15

    BRIEF-Celgene International Sàrl announces results from phase 2a SLE-001 trial evaluating CC-220

    Celgene International Sàrl: * Announced results from phase 2a SLE-001 trial evaluating CC-220, co's investigational, oral immunomodulatory compound. * Most common adverse events in trial were nausea, diarrhea and maculopapular rash. * No opportunistic infections or other systemic infections were reported in any CC-220 dose groups in trial.

  • More trends:

    Celgene CorporationCELGZ | Celladon CorporationCLDN | Celldex Therapeutics, Inc.CLDX | Cellectar Biosciences, Inc.CLRB | Cellectar Biosciences, Inc.CLRBW | Cellectis S.A.CLLS | Cellular Biomedicine Group, Inc.CBMG | Celsion CorporationCLSN | Celsus Therapeutics PlcCLTX | Celyad SACYAD |